S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

J&J Seeks FDA Approval for Caplyta in Bipolar I Mania

Johnson & Johnson has asked U.S. regulators to expand Caplyta’s approved uses to include manic or mixed episodes associated with bipolar I disorder in adults. The filing follows a late-stage study result the company reported last week and could give the drug its fifth approved use in adults.

J&J Seeks FDA Approval for Caplyta in Bipolar I Mania

The New Brunswick, N.J.-based company said its application is for treating adults with manic or mixed episodes linked to bipolar I disorder. J&J said approval would make this the fifth adult use cleared for Caplyta.

The antipsychotic is already approved for depressive episodes associated with bipolar I or II disorder, schizophrenia and major depressive disorder. Last week, J&J said Caplyta met its key goals in a second late-stage study in bipolar mania.

Caplyta was a key asset in J&J’s $14.6 billion acquisition of Intra-Cellular Therapies last year.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!